Use of LTB4 antagonists in veterinary medicine

A method for treating respiratory disease in a horse which comprises administering to the affected horse a therapeutically effective amount of a LTB4 antagonist of formula 1

• 16
• wherein
• A denotes a group of formula
• —O—CmH2m—O—(PHE)n- (II)
• wherein
• m is an integer from 2 to 6,
• n is 0 or 1,
• PHE denotes a 1,4-phenylene group optionally substituted by one or two C1-C6 alkyl groups;
• or
• A denotes a group of formula
• 17
• R1 denotes H, OH, CN, COR10, COOR10 or CHO;
• R2 denotes H, Br, Cl, F, CF3, CHF2, OH, HSO3—O, C1-C6-alkyl, C1-C6-alkoxy, C5-C7-cycloalkyl, CONR8R9, aryl, O-aryl, CH2-aryl, CR5R6-aryl, or C(CH3)2—R7,
• R3 denotes H, C1-C6-alkyl, C1-C6-alkoxy, OH, Cl or F,
• R4 denotes H or C1-C6-alkyl;
• R5 denotes C1-C4-alkyl, CF3, CH2OH, COOH or COO(C1-C4-alkyl);
• R6 denotes H, C1-C4-alkyl or CF3;
• R7 denotes CH2OH, COOH, COO(C1-C4-alkyl), CONR8R9 or CH2NR8R9;
• R8 denotes H, C1-C6-alkyl, phenyl, phenyl-(C1-C6-alkyl), COR10, COOR10, CHO, CONH2, CONHR10, SO2—(C1-C6-alkyl), SO2-phenyl, while the phenyl group may be mono- or disubstituted by Cl, F, CF3, C1-C4-alkyl, OH and/or C1-C4-alkoxy;
• R9 denotes H or C1-C6-alkyl;
• or
• R8 and R9 together represent a C4-C6-alkylene group;
• R10 denotes C1-C6-alkyl, C5-C7-cycloalkyl, aryl, heteroaryl, aralkyl or heteroaryl-(C1-C6-alkyl),
• while the aryl groups mentioned in groups R2 and R10 denote phenyl or naphthyl, the heteroaryl groups denote pyrrole, pyrazole, imidazole, furanyl, thienyl, pyridine or pyrimidine and may each be mono- or polysubstituted by Cl, F, CF3, C1-C4-alkyl, OH, HSO3—O or C1-C4-alkoxy,
• and the pharmacologically acceptable acid addition salts thereof, the glycosides and O-sulphates thereof.

A method for preventing respiratory disease in a horse which comprises administering to the horse a prophylactic amount of a LTB4 antagonist compound of formula 1

• 18
• wherein
• A denotes a group of formula
• —O—CmH2m—O—(PHE)n- (II)
• wherein
• m is an integer from 2 to 6,
• n is 0 or 1,
• PHE denotes a 1,4-phenylene group optionally substituted by one or two C1-C6 alkyl groups;
• or
• A denotes a group of formula
• 19
• R1 denotes H, OH, CN, COR10, COOR10 or CHO;
• R2 denotes H, Br, Cl, F, CF3, CHF2, OH, HSO3—O, C1-C6-alkyl, C1-C6-alkoxy, C5-C7-cycloalkyl, CONR8R9, aryl, O-aryl, CH2-aryl, CR5R6-aryl, or C(CH3)2—R7,
• R3 denotes H, C1-C6-alkyl, C1-C6-alkoxy, OH, Cl or F,
• R4 denotes H or C1-C6-alkyl;
• R5 denotes C1-C4-alkyl, CF3, CH2OH, COOH or COO(C1-C4-alkyl);
• R6 denotes H, C1-C4-alkyl or CF3;
• R7 denotes CH2OH, COOH, COO(C1-C4-alkyl), CONR8R9 or CH2NR8R9;
• R8 denotes H, C1-C6-alkyl, phenyl, phenyl-(C1-C6-alkyl), COR10, COOR10, CHO, CONH2, CONHR10, SO2—(C1-C6-alkyl), SO2-phenyl, while the phenyl group may be mono- or disubstituted by Cl, F, CF3, C1-C4-alkyl, OH and/or C1-C4-alkoxy;
• R9 denotes H or C1-C6-alkyl;
• or
• R8 and R9 together represent a C4-C6-alkylene group;
• R10 denotes C1-C6-alkyl, C5-C7-cycloalkyl, aryl, heteroaryl, aralkyl or heteroaryl-(C1-C6-alkyl),
• while the aryl groups mentioned in groups R2 and R10 denote phenyl or naphthyl, the heteroaryl groups denote pyrrole, pyrazole, imidazole, furanyl, thienyl, pyridine or pyrimidine and may each be mono- or polysubstituted by Cl, F, CF3, C1-C4-alkyl, OH, HSO3—O or C1-C4-alkoxy,
• and the pharmacologically acceptable acid addition salts thereof, the glycosides and O-sulphates thereof.